{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T21:38:16Z","timestamp":1790285896757,"version":"4.1.0"},"reference-count":142,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T00:00:00Z","timestamp":1754956800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001321","name":"National Research Foundation","doi-asserted-by":"publisher","award":["PPNT230823145247"],"award-info":[{"award-number":["PPNT230823145247"]}],"id":[{"id":"10.13039\/501100001321","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmn.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Discovery Today"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.drudis.2025.104456","type":"journal-article","created":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T23:41:37Z","timestamp":1755128497000},"page":"104456","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Adipose tissue NLRP3 inflammasome: a therapeutic target in obesity and type 2 diabetes mellitus"],"prefix":"10.1016","volume":"30","author":[{"given":"Ngozi Francisca","family":"Nnolum-Orji","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pradeep","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindokuhle Malibongwe","family":"Ngema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3889-1529","authenticated-orcid":false,"given":"Yahya Essop","family":"Choonara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drudis.2025.104456_b0005","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1056\/NEJMe1706095","article-title":"Global health effects of overweight and obesity","volume":"377","author":"Gregg","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.drudis.2025.104456_b0010","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/S2213-8587(14)70004-X","article-title":"Combating the dual burden: therapeutic targeting of common pathways in obesity and type 2 diabetes","volume":"2","author":"Scheen","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.drudis.2025.104456_b0015","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.diabres.2017.03.024","article-title":"IDF Diabetes Atlas: global estimates for the prevalence of diabetes for 2015 and 2040","volume":"128","author":"Ogurtsova","year":"2017","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.drudis.2025.104456_b0020","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1046\/j.1467-789x.2000.00013.x","article-title":"Redefining type 2 diabetes: \u2018diabesity\u2019 or \u2018obesity dependent diabetes mellitus\u2019?","volume":"20","author":"Astrup","year":"2000","journal-title":"Obes Rev"},{"key":"10.1016\/j.drudis.2025.104456_b0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.atherosclerosis.2025.120424","article-title":"Unlocking the secrets: adipose tissue dysfunction and atherosclerosis-mechanisms and innovative therapeutic approaches","volume":"408","author":"Matar","year":"2025","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.drudis.2025.104456_b0030","doi-asserted-by":"crossref","first-page":"451","DOI":"10.2147\/DMSO.S333787","article-title":"Risk factors analysis and management of cardiometabolic-based chronic disease in low- and middle-income countries","volume":"15","author":"Dutt","year":"2022","journal-title":"Diabetes, Metab Syndr Obes"},{"key":"10.1016\/j.drudis.2025.104456_b0035","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.cmi.2021.09.010","article-title":"Obesity, diabetes, hypertension and severe outcomes among inpatients with coronavirus disease 2019: a nationwide study","volume":"28","author":"Bailly","year":"2022","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.drudis.2025.104456_b0040","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1152\/ajpendo.00198.2020","article-title":"Obesity and COVID-19\u00a0: immune and metabolic derangement as a possible link to adverse clinical outcome","volume":"2","author":"Korakas","year":"2020","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1016\/j.drudis.2025.104456_b0045","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1016\/j.numecd.2020.05.014","article-title":"Diabetes as a risk factor for greater COVID-19 severity and in-hospital death: a meta-analysis of observational studies","volume":"30","author":"Mantovani","year":"2020","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"10.1016\/j.drudis.2025.104456_b0050","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/s12325-018-0824-8","article-title":"Body weight considerations in the management of type 2 diabetes","volume":"36","author":"Apovian","year":"2019","journal-title":"Adv Ther"},{"key":"10.1016\/j.drudis.2025.104456_b0055","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1016\/S0140-6736(22)02403-5","article-title":"Contemporary medical, device, and surgical therapies for obesity in adults","volume":"401","author":"Perdomo","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.drudis.2025.104456_b0060","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1038\/s41591-024-03412-w","article-title":"Mapping the effectiveness and risks of GLP-1 receptor agonists","volume":"31","author":"Xie","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.drudis.2025.104456_b0065","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1136\/flgastro-2024-102995","article-title":"Anti-obesity drugs for the gastroenterologist","volume":"16","author":"Sharkey","year":"2025","journal-title":"Frontline Gastroenterol"},{"key":"10.1016\/j.drudis.2025.104456_b0070","first-page":"229","article-title":"Sglt2 inhibitors: a narrative review of efficacy and safety","volume":"121","author":"Nelinson","year":"2021","journal-title":"J Am Osteopath Assoc"},{"key":"10.1016\/j.drudis.2025.104456_b0075","doi-asserted-by":"crossref","first-page":"56","DOI":"10.2174\/1872214810666160219163314","article-title":"Inflammasome as a new therapeutic target for diabetic complications","volume":"10","author":"Volpe","year":"2016","journal-title":"Recent Pat Endocr Metab Immune Drug Discov"},{"key":"10.1016\/j.drudis.2025.104456_b0080","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.cmet.2011.10.011","article-title":"The inflammasome puts obesity in the danger zone","volume":"15","author":"Stienstra","year":"2012","journal-title":"Cell Metab"},{"key":"10.1016\/j.drudis.2025.104456_b0085","first-page":"197","article-title":"The adipose tissue as a source of vasoactive factors","volume":"2","author":"Fr\u00fchbeck","year":"2004","journal-title":"Curr Med Chem Cardiovasc Hematol Agents"},{"key":"10.1016\/j.drudis.2025.104456_b0090","doi-asserted-by":"crossref","first-page":"2822","DOI":"10.3390\/nu16172822","article-title":"The role of inflammatory mediators in the pathogenesis of obesity","volume":"16","author":"Bakinowska","year":"2024","journal-title":"Nutrients"},{"key":"10.1016\/j.drudis.2025.104456_b0095","doi-asserted-by":"crossref","first-page":"357","DOI":"10.3390\/cimb47050357","article-title":"The mechanisms of chronic inflammation in obesity and potential therapeutic strategies: a narrative review","volume":"47","author":"Gkrinia","year":"2025","journal-title":"Curr Issues Mol Biol"},{"key":"10.1016\/j.drudis.2025.104456_b0100","article-title":"Cytokines as key players in obesity low grade inflammation and related complications","volume":"54","author":"Uti","year":"2025","journal-title":"Obes Med"},{"key":"10.1016\/j.drudis.2025.104456_b0105","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/j.1463-1326.2009.01175.x","article-title":"Diabetes and obesity: therapeutic targeting and risk reduction \u2013 a complex interplay","volume":"12","author":"Niswender","year":"2010","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.drudis.2025.104456_b0110","doi-asserted-by":"crossref","first-page":"130","DOI":"10.4239\/wjd.v14.i3.130","article-title":"Pancreatic \u03b2-cell dysfunction in type 2 diabetes: Implications of inflammation and oxidative stress","volume":"14","author":"Dludla","year":"2023","journal-title":"World J Diabetes"},{"key":"10.1016\/j.drudis.2025.104456_b0115","unstructured":"Chadt A, Scherneck S, Joost H-G, Al-Hasani H. Molecular links between obesity and diabetes: \u201cdiabesity\u201d. In: Feingold KR, et al., eds. Endotext 2018. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK279051\/."},{"key":"10.1016\/j.drudis.2025.104456_b0120","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.3389\/fphys.2019.01607","article-title":"Chronic adipose tissue inflammation linking obesity to insulin resistance and type 2 diabetes","volume":"10","author":"Zatterale","year":"2020","journal-title":"Front Physiol"},{"key":"10.1016\/j.drudis.2025.104456_b0125","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s11010-016-2878-8","article-title":"Protein kinases: mechanisms and downstream targets in inflammation-mediated obesity and insulin resistance","volume":"426","author":"Nandipati","year":"2017","journal-title":"Mol Cell Biochem"},{"key":"10.1016\/j.drudis.2025.104456_b0130","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1146\/annurev-immunol-031210-101322","article-title":"Inflammatory mechanisms in obesity","volume":"29","author":"Gregor","year":"2011","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.drudis.2025.104456_b0135","doi-asserted-by":"crossref","first-page":"3351","DOI":"10.3390\/ijms22073351","article-title":"Potential of nutraceutical supplementation in the modulation of white and brown fat tissues in obesity-associated disorders: role of inflammatory signalling","volume":"22","author":"Scarano","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.drudis.2025.104456_b0140","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1126\/science.1061620","article-title":"Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikk\u03b2","volume":"293","author":"Yuan","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.drudis.2025.104456_b0145","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1111\/obr.12862","article-title":"Lipotoxicity plays a key role in the development of both insulin resistance and muscle atrophy in patients with type 2 diabetes","volume":"20","author":"Meex","year":"2019","journal-title":"Obes Rev"},{"key":"10.1016\/j.drudis.2025.104456_b0150","doi-asserted-by":"crossref","first-page":"602","DOI":"10.3389\/fphys.2017.00602","article-title":"Dietary capsaicin improves glucose homeostasis and alters the gut microbiota in obese diabetic ob\/ob mice","volume":"8","author":"Song","year":"2017","journal-title":"Front Physiol"},{"key":"10.1016\/j.drudis.2025.104456_b0155","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.3390\/nu13041060","article-title":"Dietary management of type 2 diabetes in the mena region: a review of the evidence","volume":"13","author":"Hwalla","year":"2021","journal-title":"Nutrients"},{"key":"10.1016\/j.drudis.2025.104456_b0160","doi-asserted-by":"crossref","first-page":"9818","DOI":"10.3390\/ijms24129818","article-title":"Molecular mechanisms for the vicious cycle between insulin resistance and the inflammatory response in obesity","volume":"24","author":"Szukiewicz","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.drudis.2025.104456_b0165","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3389\/fimmu.2018.02509","article-title":"T cells in adipose tissue: critical players in immunometabolism","volume":"9","author":"Wang","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.drudis.2025.104456_b0170","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1159\/000497124","article-title":"The ABCD of obesity: an EASO position statement on a diagnostic term with clinical and scientific implications","volume":"12","author":"Fr\u00fchbeck","year":"2019","journal-title":"Obes Facts"},{"key":"10.1016\/j.drudis.2025.104456_b0175","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s13098-019-0450-x","article-title":"Assessment of adiposity distribution and its association with diabetes and insulin resistance: a population-based study","volume":"11","author":"Sun","year":"2019","journal-title":"Diabetol Metab Syndr"},{"key":"10.1016\/j.drudis.2025.104456_b0180","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.jacc.2019.11.044","article-title":"Cardiometabolic-based chronic disease, adiposity and dysglycemia drivers","volume":"75","author":"Mechanick","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.drudis.2025.104456_b0185","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1017\/S0007114522002963","article-title":"Prevalence of adiposity-based chronic disease and its association with anthropometric and clinical indices: a cross-sectional study","volume":"130","author":"Gonz\u00e1lez-Salazar","year":"2023","journal-title":"Br J Nutr"},{"key":"10.1016\/j.drudis.2025.104456_b0190","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1007\/s12272-013-0023-8","article-title":"Adipose tissue macrophages in the development of obesity-induced inflammation, insulin resistance and type 2 diabetes","volume":"36","author":"Lee","year":"2013","journal-title":"Arch Pharm Res"},{"key":"10.1016\/j.drudis.2025.104456_b0195","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.tips.2018.03.001","article-title":"Macrophage-targeted therapeutics for metabolic disease","volume":"39","author":"Peterson","year":"2018","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.drudis.2025.104456_b0200","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.cell.2015.02.022","article-title":"Immune regulation of metabolic homeostasis in health and disease","volume":"161","author":"Brestoff","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.drudis.2025.104456_b0205","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.bbalip.2009.12.006","article-title":"Adipose tissue expandability, lipotoxicity and the metabolic syndrome \u2013 an allostatic perspective","volume":"1801","author":"Virtue","year":"2010","journal-title":"Biochim Biophys Acta \u2013 Mol Cell Biol Lipids"},{"key":"10.1016\/j.drudis.2025.104456_b0210","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1128\/MCB.01300-08","article-title":"Metabolic dysregulation and adipose tissue fibrosis: role of collagen VI","volume":"29","author":"Khan","year":"2009","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.drudis.2025.104456_b0215","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fnagi.2022.879021","article-title":"The NLRP3 inflammasome pathway: a review of mechanisms and inhibitors for the treatment of inflammatory diseases","volume":"14","author":"Blevins","year":"2022","journal-title":"Front Aging Neurosci"},{"key":"10.1016\/j.drudis.2025.104456_b0220","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abn7583","article-title":"Directionality of PYD filament growth determined by the transition of NLRP3 nucleation seeds to ASC elongation","volume":"8","author":"Hochheiser","year":"2022","journal-title":"Sci Adv"},{"key":"10.1016\/j.drudis.2025.104456_b0225","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1146\/annurev-immunol-081022-021207","article-title":"Structural mechanisms of NLRP3 inflammasome assembly and activation","volume":"41","author":"Fu","year":"2023","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.drudis.2025.104456_b0230","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fimmu.2020.01444","article-title":"NLRP3 inflammasome activation in cancer: a double-edged sword","volume":"11","author":"Hamarsheh","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.drudis.2025.104456_b0235","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/s41577-019-0165-0","article-title":"The NLRP3 inflammasome: molecular activation and regulation to therapeutics","volume":"19","author":"Swanson","year":"2021","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.drudis.2025.104456_b0240","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/biomedicines8120598","article-title":"The role of soluble uric acid in modulating autophagy flux and inflammasome activation during bacterial infection in macrophages","volume":"8","author":"Al-Awad","year":"2020","journal-title":"Biomedicines"},{"key":"10.1016\/j.drudis.2025.104456_b0245","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/s41419-021-03445-w","article-title":"Sensing soluble uric acid by Naip1-Nlrp3 platform","volume":"12","author":"Braga","year":"2021","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.drudis.2025.104456_b0250","first-page":"1","article-title":"The inflammasome signaling pathway responds to pathogens or danger signals by assembling inflammasomes, with NLRP3 serving as a prominent sensor. Activation of the inflammasome triggers caspase-1 activation, leading to the cleavage of pro-IL-1\u03b2 and pro-IL","volume":"20","author":"Kelley","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.drudis.2025.104456_b0255","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1038\/s41423-021-00670-3","article-title":"An update on the regulatory mechanisms of NLRP3 inflammasome activation","volume":"18","author":"Paik","year":"2021","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.drudis.2025.104456_b0260","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1097\/CM9.0000000000001214","article-title":"NLRP3 inflammasome: a new therapeutic target for high-risk reproductive disorders?","volume":"134","author":"Zhou","year":"2021","journal-title":"Chin Med J"},{"key":"10.1016\/j.drudis.2025.104456_b0265","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41421-020-0167-x","article-title":"Inflammasome activation and regulation: toward a better understanding of complex mechanisms","volume":"6","author":"Zheng","year":"2020","journal-title":"Cell Discov"},{"key":"10.1016\/j.drudis.2025.104456_b0270","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/s41419-019-1413-8","article-title":"Recent advances in the mechanisms of NLRP3 inflammasome activation and its inhibitors","volume":"10","author":"Yang","year":"2019","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.drudis.2025.104456_b0275","first-page":"1","article-title":"NLRP3 inflammasome activation in adipose tissues and its implications on metabolic diseases","volume":"21","author":"Wu","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.drudis.2025.104456_b0280","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1038\/nri2725","article-title":"NLRP3 inflammasome activation: the convergence of multiple signalling pathways on ROS production?","volume":"10","author":"Tschopp","year":"2010","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.drudis.2025.104456_b0285","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/nature09663","article-title":"A role for mitochondria in NLRP3 inflammasome activation","volume":"469","author":"Zhou","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2025.104456_b0290","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/nm.2279","article-title":"The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance","volume":"17","author":"Vandanmagsar","year":"2011","journal-title":"Nat Med"},{"key":"10.1016\/j.drudis.2025.104456_b0295","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/j.cmet.2014.03.029","article-title":"Adipose tissue macrophages promote myelopoiesis and monocytosis in obesity","volume":"19","author":"Nagareddy","year":"2014","journal-title":"Cell Metab"},{"key":"10.1016\/j.drudis.2025.104456_b0300","first-page":"593","article-title":"The inflammasome-mediated caspase-1 activation controls adipocyte differentiation and insulin sensitivity","volume":"12","author":"Stienstra","year":"2010","journal-title":"Cytokine"},{"key":"10.1016\/j.drudis.2025.104456_b0305","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0139764","article-title":"Effect of roux-en-y gastric bypass on the NLRP3 inflammasome in adipose tissue from obese rats","volume":"10","author":"Mocanu","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.drudis.2025.104456_b0310","doi-asserted-by":"crossref","first-page":"15324","DOI":"10.1073\/pnas.1100255108","article-title":"Inflammasome is a central player in the induction of obesity and insulin resistance","volume":"108","author":"Stienstra","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.drudis.2025.104456_b0315","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1038\/ni.2022","article-title":"Fatty acid-induced NLRP3-ASC inflammasome activation interferes with insulin signaling","volume":"12","author":"Wen","year":"2011","journal-title":"Nat Immunol"},{"key":"10.1016\/j.drudis.2025.104456_b0320","first-page":"1","article-title":"Sodium butyrate alleviates adipocyte inflammation by inhibiting NLRP3 pathway","volume":"5","author":"Wang","year":"2015","journal-title":"Sci Rep"},{"key":"10.1016\/j.drudis.2025.104456_b0325","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.mce.2014.06.018","article-title":"Transcriptome analysis of human adipocytes implicates the NOD-like receptor pathway in obesity-induced adipose inflammation","volume":"394","author":"Yin","year":"2014","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.drudis.2025.104456_b0330","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/nm.2279","article-title":"The NALP3\/NLRP3 inflammasome instigates obesity-induced autoinflammation and insulin resistance","volume":"17","author":"Vandanmagsar","year":"2011","journal-title":"Nat Med"},{"key":"10.1016\/j.drudis.2025.104456_b0335","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.1002\/stem.2429","article-title":"Obesity and type 2 diabetes alters the immune properties of human adipose derived stem cells","volume":"34","author":"Serena","year":"2016","journal-title":"Stem Cells"},{"key":"10.1016\/j.drudis.2025.104456_b0340","doi-asserted-by":"crossref","first-page":"610","DOI":"10.2337\/db15-1478","article-title":"A role of the inflammasome in the low storage capacity of the abdominal subcutaneous adipose tissue in obese adolescents","volume":"65","author":"Kursawe","year":"2016","journal-title":"Diabetes"},{"key":"10.1016\/j.drudis.2025.104456_b0345","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1007\/s00125-013-3023-9","article-title":"Obesity phenotype is related to NLRP3 inflammasome activity and immunological profile of visceral adipose tissue","volume":"56","author":"Esser","year":"2013","journal-title":"Diabetologia"},{"key":"10.1016\/j.drudis.2025.104456_b0350","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.atherosclerosis.2015.07.043","article-title":"Expression of NLRP3 in subcutaneous adipose tissue is associated with coronary atherosclerosis","volume":"242","author":"Bando","year":"2015","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.drudis.2025.104456_b0355","doi-asserted-by":"crossref","first-page":"194","DOI":"10.2337\/db12-0420","article-title":"Upregulated NLRP3 inflammasome activation in patients with type 2 diabetes","volume":"62","author":"Lee","year":"2013","journal-title":"Diabetes"},{"key":"10.1016\/j.drudis.2025.104456_b0360","doi-asserted-by":"crossref","first-page":"3720","DOI":"10.1182\/blood-2010-07-273417","article-title":"Interleukin-1 in the pathogenesis and treatment of inflammatory diseases Interleukin-1 in the pathogenesis and treatment of inflammatory diseases","volume":"117","author":"Dinarello","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.drudis.2025.104456_b0365","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/biom9120850","article-title":"Modulatory mechanisms of the NLRP3 inflammasomes in diabetes","volume":"9","author":"Ding","year":"2019","journal-title":"Biomolecules"},{"key":"10.1016\/j.drudis.2025.104456_b0370","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1038\/s41423-019-0296-z","article-title":"NLRP3 inflammasome blockade reduces adipose tissue inflammation and extracellular matrix remodeling","volume":"18","author":"Unamuno","year":"2021","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.drudis.2025.104456_b0375","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.2337\/db13-1511","article-title":"T cell-derived IL-22 amplifies IL-1\u03b2-driven inflammation in human adipose tissue: relevance to obesity and type 2 diabetes","volume":"63","author":"Dalmas","year":"2014","journal-title":"Diabetes"},{"key":"10.1016\/j.drudis.2025.104456_b0380","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1210\/en.2006-0692","article-title":"Interleukin-1\u03b2-induced insulin resistance in adipocytes through down-regulation of insulin receptor substrate-1 expression","volume":"148","author":"Jager","year":"2007","journal-title":"Endocrinology"},{"key":"10.1016\/j.drudis.2025.104456_b0385","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1038\/ni.1831","article-title":"Thioredoxin-interacting protein links oxidative stress to inflammasome activation","volume":"11","author":"Zhou","year":"2010","journal-title":"Nat Immunol"},{"key":"10.1016\/j.drudis.2025.104456_b0390","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1038\/ijo.2016.74","article-title":"Intervention with a caspase-1 inhibitor reduces obesity-associated hyperinsulinemia, non-alcoholic steatohepatitis and hepatic fibrosis in LDLR\u2013\/\u2013 Leiden mice","volume":"40","author":"Morrison","year":"2016","journal-title":"Int J Obes"},{"key":"10.1016\/j.drudis.2025.104456_b0395","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1083\/jcb.200903124","article-title":"Glyburide inhibits the Cryopyrin\/Nalp3 inflammasome","volume":"187","author":"Lamkanfi","year":"2009","journal-title":"J Cell Biol"},{"key":"10.1016\/j.drudis.2025.104456_b0400","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41420-020-0245-8","article-title":"Metformin inhibits IL-1\u03b2 secretion via impairment of NLRP3 inflammasome in keratinocytes: implications for preventing the development of psoriasis","volume":"6","author":"Tsuji","year":"2020","journal-title":"Cell Death Discov"},{"key":"10.1016\/j.drudis.2025.104456_b0405","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1093\/jrr\/rraa062","article-title":"Rosiglitazone ameliorates radiation-induced intestinal inflammation in rats by inhibiting NLRP3 inflammasome and TNF-\u03b1 production","volume":"61","author":"Hu","year":"2020","journal-title":"J Radiat Res"},{"key":"10.1016\/j.drudis.2025.104456_b0410","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.amjmed.2025.01.021","article-title":"Mechanisms of GLP-1 receptor agonist-induced weight loss: a review of central and peripheral pathways in appetite and energy regulation","volume":"138","author":"Moiz","year":"2025","journal-title":"Am J Med"},{"key":"10.1016\/j.drudis.2025.104456_b0415","article-title":"GLP-1 alleviates NLRP3 inflammasome-dependent inflammation in perivascular adipose tissue by inhibiting the NF-\u03baB signalling pathway","volume":"49","author":"Chen","year":"2021","journal-title":"J Int Med Res"},{"key":"10.1016\/j.drudis.2025.104456_b0420","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1038\/nm.3804","article-title":"The ketone metabolite \u03b2-hydroxybutyrate blocks NLRP3 inflammasome-mediated inflammatory disease","volume":"21","author":"Youm","year":"2015","journal-title":"Nat Med"},{"key":"10.1016\/j.drudis.2025.104456_b0425","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.14336\/AD.2021.0318","article-title":"Targeting NLRP3 inflammasome in the treatment of diabetes and diabetic complications: role of natural compounds from herbal medicine","volume":"12","author":"Bai","year":"2021","journal-title":"Aging Dis"},{"key":"10.1016\/j.drudis.2025.104456_b0430","article-title":"Quercetin and allopurinol ameliorate kidney injury in STZ-treated rats with regulation of renal NLRP3 inflammasome activation and lipid accumulation","volume":"7","author":"Wang","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.drudis.2025.104456_b0435","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/1516985","article-title":"Curcumin ameliorates diabetic nephropathy by suppressing NLRP3 inflammasome signaling","volume":"2017","author":"Lu","year":"2017","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.drudis.2025.104456_b0440","article-title":"Epigallocatechin-3-gallate prevents inflammation and diabetes-induced glucose tolerance through inhibition of NLRP3 inflammasome activation","volume":"2021","author":"Zhang","year":"2021","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.drudis.2025.104456_b0445","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1016\/j.immuni.2013.05.015","article-title":"Omega-3 fatty acids prevent inflammation and metabolic disorder through inhibition of NLRP3 inflammasome activation","volume":"38","author":"Yan","year":"2013","journal-title":"Immunity"},{"key":"10.1016\/j.drudis.2025.104456_b0450","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/s41589-019-0277-7","article-title":"MCC950 directly targets the NLRP3 ATP-hydrolysis motif for inflammasome inhibition","volume":"15","author":"Coll","year":"2019","journal-title":"Nat Chem Biol"},{"key":"10.1016\/j.drudis.2025.104456_b0455","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2020.108305","article-title":"NLRP3 inflammasome inhibition with MCC950 improves insulin sensitivity and inflammation in a mouse model of frontotemporal dementia","volume":"180","author":"Hull","year":"2020","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.drudis.2025.104456_b0460","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.1084\/jem.20171419","article-title":"Identification of a selective and direct NLRP3 inhibitor to treat inflammatory disorders","volume":"214","author":"Jiang","year":"2017","journal-title":"J Exp Med"},{"key":"10.1016\/j.drudis.2025.104456_b0465","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15252\/emmm.201708689","article-title":"Tranilast directly targets NLRP 3 to treat inflammasome\u2010driven diseases","volume":"10","author":"Huang","year":"2018","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.drudis.2025.104456_b0470","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s40268-022-00382-7","article-title":"NLRP3 inhibitor tranilast attenuates gestational diabetes mellitus in a genetic mouse model","volume":"22","author":"Cao","year":"2022","journal-title":"Drugs R D"},{"key":"10.1016\/j.drudis.2025.104456_b0475","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/3206587","article-title":"Compound C protects mice from HFD-induced obesity and nonalcoholic fatty liver disease","volume":"2019","author":"Wang","year":"2019","journal-title":"Int J Endocrinol"},{"key":"10.1016\/j.drudis.2025.104456_b0480","doi-asserted-by":"crossref","first-page":"E1530","DOI":"10.1073\/pnas.1716095115","article-title":"OLT1177, a \u03b2-sulfonyl nitrile compound, safe in humans, inhibits the NLRP3 inflammasome and reverses the metabolic cost of inflammation","volume":"115","author":"Marchetti","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.drudis.2025.104456_b0485","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/j.bbrc.2020.11.009","article-title":"NLRP3 inflammasome inhibitor CY-09 reduces hepatic steatosis in experimental NAFLD mice","volume":"534","author":"Wang","year":"2021","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.drudis.2025.104456_b0490","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/FJC.0000000000000931","article-title":"Phase 1B, randomized, double-blinded, dose escalation, single-center, repeat dose safety and pharmacodynamics study of the oral NLRP3 inhibitor dapansutrile in subjects with NYHA II-III systolic heart failure","volume":"77","author":"Wohlford","year":"2021","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.drudis.2025.104456_b0495","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.celrep.2018.09.058","article-title":"Salt-responsive metabolite, \u03b2-hydroxybutyrate, attenuates hypertension","volume":"25","author":"Chakraborty","year":"2018","journal-title":"Cell Rep"},{"key":"10.1016\/j.drudis.2025.104456_b0500","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2020.107358","article-title":"NLRP3 inflammasome inhibitor INF39 attenuated NLRP3 assembly in macrophages","volume":"92","author":"Shi","year":"2021","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.drudis.2025.104456_b0505","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1124\/jpet.123.002013","article-title":"Reversal of high fat diet-induced obesity, systemic inflammation, and astrogliosis by the NLRP3 inflammasome inhibitors NT-0249 and NT-0796","volume":"388","author":"Thornton","year":"2024","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.drudis.2025.104456_b0510","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fimmu.2024.1422249","article-title":"Screening NLRP3 drug candidates in clinical development: lessons from existing and emerging technologies","volume":"15","author":"Tengesdal","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.drudis.2025.104456_b0515","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1021\/acschembio.1c00218","article-title":"A probe for NLRP3 inflammasome inhibitor MCC950 identifies carbonic anhydrase 2 as a novel target","volume":"16","author":"Kennedy","year":"2021","journal-title":"ACS Chem Biol"},{"key":"10.1016\/j.drudis.2025.104456_b0520","doi-asserted-by":"crossref","first-page":"3435","DOI":"10.1007\/s11695-020-04571-8","article-title":"Sleeve gastroplasty combined with the NLRP3 inflammasome inhibitor CY-09 reduces body weight, improves insulin resistance and alleviates hepatic steatosis in mouse model","volume":"30","author":"Sun","year":"2020","journal-title":"Obes Surg"},{"key":"10.1016\/j.drudis.2025.104456_b0525","first-page":"562","article-title":"Potential of beta-hydroxybutyrate (BHB) in the management of type 2 diabetes and risk of ketoacidosis in diabetic patients","volume":"7","author":"Balapadang","year":"2024","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.drudis.2025.104456_b0530","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0104771","article-title":"NLRP3 gene silencing ameliorates diabetic cardiomyopathy in a type 2 diabetes rat model","volume":"9","author":"Luo","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.drudis.2025.104456_b0535","doi-asserted-by":"crossref","first-page":"30094","DOI":"10.1074\/jbc.M113.494286","article-title":"Cathepsin B contributes to autophagy-related 7 proinflammatory response and aggravates lipotoxicity in rat insulinoma cell line","volume":"288","author":"Li","year":"2013","journal-title":"J Biol Chem"},{"key":"10.1016\/j.drudis.2025.104456_b0540","doi-asserted-by":"crossref","first-page":"4092","DOI":"10.1038\/s41467-018-06522-5","article-title":"Targeting of NLRP3 inflammasome with gene editing for the amelioration of inflammatory diseases","volume":"9","author":"Xu","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.drudis.2025.104456_b0545","doi-asserted-by":"crossref","first-page":"727","DOI":"10.3390\/cells8070727","article-title":"Overview of extracellular vesicles, their origin, composition, purpose, and methods for exosome isolation and analysis","volume":"8","author":"Doyle","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.drudis.2025.104456_b0550","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.jbiosc.2021.02.007","article-title":"Exosomes from adipose derived mesenchymal stem cells alleviate diabetic osteoporosis in rats through suppressing NLRP3 inflammasome activation in osteoclasts","volume":"131","author":"Zhang","year":"2021","journal-title":"J Biosci Bioeng"},{"key":"10.1016\/j.drudis.2025.104456_b0555","doi-asserted-by":"crossref","DOI":"10.1155\/2023\/5584894","article-title":"Human umbilical cord mesenchymal stem cells inhibit pyroptosis of renal tubular epithelial cells through miR-342-3p\/caspase1 signaling pathway in diabetic nephropathy","volume":"2023","author":"Zheng","year":"2023","journal-title":"Stem Cells Int"},{"key":"10.1016\/j.drudis.2025.104456_b0560","doi-asserted-by":"crossref","first-page":"9544","DOI":"10.18632\/aging.205034","article-title":"Human umbilical cord mesenchymal stem cells-derived exosomes exert anti-inflammatory effects on osteoarthritis chondrocytes","volume":"15","author":"Wang","year":"2023","journal-title":"Aging"},{"key":"10.1016\/j.drudis.2025.104456_b0565","doi-asserted-by":"crossref","DOI":"10.1080\/0886022X.2023.2177082","article-title":"Bone marrow mesenchymal stem cell-derived exosomal miR-30e-5p ameliorates high-glucose induced renal proximal tubular cell pyroptosis by inhibiting ELAVL1","volume":"45","author":"Lv","year":"2023","journal-title":"Ren Fail"},{"key":"10.1016\/j.drudis.2025.104456_b0570","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s00281-019-00743-6","article-title":"Treatment of type 2 diabetes by targeting interleukin-1: a meta-analysis of 2921 patients","volume":"41","author":"Kataria","year":"2019","journal-title":"Semin Immunopathol"},{"key":"10.1016\/j.drudis.2025.104456_b0575","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1056\/NEJMoa065213","article-title":"Interleukin-1\u2013receptor antagonist in type 2 diabetes mellitus","volume":"356","author":"Larsen","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.drudis.2025.104456_b0580","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/ar2143","article-title":"A pilot study of IL-1 inhibition by anakinra in acute gout","volume":"9","author":"So","year":"2007","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.drudis.2025.104456_b0585","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.2337\/dc09-0533","article-title":"Sustained effects of interleukin-1 receptor antagonist treatment in type 2 diabetes","volume":"32","author":"Larsen","year":"2009","journal-title":"Diabetes Care"},{"key":"10.1016\/j.drudis.2025.104456_b0590","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pmed.1002901","article-title":"Anti-interleukin-1 treatment in patients with rheumatoid arthritis and type 2 diabetes (TRACK): a multicentre, open-label, randomised controlled trial","volume":"16","author":"Ruscitti","year":"2019","journal-title":"PLoS Med"},{"key":"10.1016\/j.drudis.2025.104456_b0595","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1161\/HYPERTENSIONAHA.119.13982","article-title":"IL (Interleukin)-1 receptor antagonist increases Ang (Angiotensin [1\u20137]) and decreases blood pressure in obese individuals","volume":"75","author":"Urwyler","year":"2020","journal-title":"Hypertension"},{"key":"10.1016\/j.drudis.2025.104456_b0600","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s00125-024-06306-1","article-title":"Targeting the NLRP3 inflammasome\u2013IL-1\u03b2 pathway in type 2 diabetes and obesity","volume":"68","author":"Meier","year":"2024","journal-title":"Diabetologia"},{"key":"10.1016\/j.drudis.2025.104456_b0605","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with canakinumab for atherosclerotic disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.drudis.2025.104456_b0610","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1016\/j.jacc.2018.03.002","article-title":"Anti-inflammatory therapy with canakinumab for the prevention and management of diabetes","volume":"71","author":"Everett","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.drudis.2025.104456_b0615","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1161\/CIRCULATIONAHA.118.038010","article-title":"Anti-inflammatory therapy with canakinumab for the prevention of hospitalization for heart failure","volume":"139","author":"Everett","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.drudis.2025.104456_b0620","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.jmb.2012.09.021","article-title":"One target - two different binding modes: structural insights into gevokizumab and canakinumab interactions to interleukin-1\u03b2","volume":"425","author":"Blech","year":"2013","journal-title":"J Mol Biol"},{"key":"10.1016\/j.drudis.2025.104456_b0625","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/7297419","article-title":"Targeting inflammatory cytokines to improve type 2 diabetes control","volume":"2021","author":"Velikova","year":"2021","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.drudis.2025.104456_b0630","unstructured":"Olatec Initiates Dapansutrile Phase II Diabetes Trial. Clinical Trials Arena Website. https:\/\/www.clinicaltrialsarena.com\/news\/olatec-dapansutrile-diabetes-trial [Accessed 9 August 2025]."},{"key":"10.1016\/j.drudis.2025.104456_b0635","unstructured":"Ventyx Biosciences Highlights 2025 Pipeline Strategy and Provides Clinical Updates on its NLRP3 Inhibitor Portfolio. Ventyx Biosciences Website. https:\/\/ir.ventyxbio.com\/news-releases\/news-release-details\/ventyx-biosciences-highlights-2025-pipeline-strategy-and [Accessed 9 August 2025]."},{"key":"10.1016\/j.drudis.2025.104456_b0640","unstructured":"NodThera\u2019s NLRP3 Inhibitor NT-0796 Meets Primary Endpoint of Inflammation Reversal in Phase Ib\/IIa Trial in Obese Subjects with Cardiovascular Risk. NodThera Website. www.nodthera.com\/news\/nodtheras-nlrp3-inhibitor-nt-0796 [Accessed 9 August 2025]."},{"key":"10.1016\/j.drudis.2025.104456_b0645","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1038\/nrd.2018.97","article-title":"Targeting the NLRP3 inflammasome in inflammatory diseases","volume":"17","author":"Mangan","year":"2018","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.drudis.2025.104456_b0650","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12964-024-01932-z","article-title":"The role of pyroptosis in cancer: key components and therapeutic potential","volume":"22","author":"Liu","year":"2024","journal-title":"Cell Commun Signal"},{"key":"10.1016\/j.drudis.2025.104456_b0655","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1290885","article-title":"Pyroptosis: shedding light on the mechanisms and links with cancers","volume":"14","author":"You","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.drudis.2025.104456_b0660","doi-asserted-by":"crossref","first-page":"485","DOI":"10.3390\/cancers15020485","article-title":"Obesity and cancer: a current overview of epidemiology, pathogenesis, outcomes, and management","volume":"15","author":"Pati","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.drudis.2025.104456_b0665","doi-asserted-by":"crossref","first-page":"2918","DOI":"10.3389\/fimmu.2018.02918","article-title":"NLRP3 inflammasome: a possible link between obesity-associated low-grade chronic inflammation and colorectal cancer development","volume":"9","author":"Ahechu","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.drudis.2025.104456_b0670","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/bib\/bbaa345","article-title":"Pan-cancer analysis of NLRP3 inflammasome with potential implications in prognosis and immunotherapy in human cancer","volume":"22","author":"Ju","year":"2021","journal-title":"Brief Bioinform"},{"key":"10.1016\/j.drudis.2025.104456_b0675","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.tips.2025.04.007","article-title":"Targeting the NLRP3 inflammasome for inflammatory disease therapy","volume":"46","author":"Cabral","year":"2025","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.drudis.2025.104456_b0680","first-page":"8","article-title":"Unraveling molecular interconnections and identifying potential therapeutic targets of significance in obesity-cancer link","volume":"5","author":"Abdulla","year":"2025","journal-title":"J Natl Cancer Cent"},{"key":"10.1016\/j.drudis.2025.104456_b0685","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2023.108545","article-title":"NLRP3 and cancer: pathogenesis and therapeutic opportunities","volume":"251","author":"Tengesdal","year":"2023","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.drudis.2025.104456_b0690","first-page":"24756","article-title":"Inhibition of NLRP3 inflammasome contributes to paclitaxel efficacy in triple negative breast cancer treatment","volume":"14","author":"St\u0103mat","year":"2024","journal-title":"Sci Rep"},{"key":"10.1016\/j.drudis.2025.104456_b0695","article-title":"Immune cells combined with NLRP3 inflammasome inhibitor exert better antitumor effect on pancreatic ductal adenocarcinoma","volume":"10","author":"Liu","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.drudis.2025.104456_b0700","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2025.1614438","article-title":"Targeting the NLRP3 inflammasome for calcium oxalate stones: pathophysiology and emerging pharmacological interventions","volume":"16","author":"Boldt","year":"2025","journal-title":"Front Physiol"},{"key":"10.1016\/j.drudis.2025.104456_b0705","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/s41435-020-0104-x","article-title":"Inflammasome inhibition under physiological and pharmacological conditions","volume":"21","author":"Caseley","year":"2020","journal-title":"Genes Immun"},{"key":"10.1016\/j.drudis.2025.104456_b0710","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.115621","article-title":"Polydatin protects against calcium oxalate crystal-induced renal injury through the cytoplasmic\/mitochondrial reactive oxygen species-NLRP3 inflammasome pathway","volume":"167","author":"Liu","year":"2023","journal-title":"Biomed Pharmacother"}],"container-title":["Drug Discovery Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644625001692?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644625001692?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T11:54:56Z","timestamp":1772884496000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359644625001692"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":142,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S1359644625001692"],"URL":"https:\/\/doi.org\/10.1016\/j.drudis.2025.104456","relation":{},"ISSN":["1359-6446"],"issn-type":[{"value":"1359-6446","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adipose tissue NLRP3 inflammasome: a therapeutic target in obesity and type 2 diabetes mellitus","name":"articletitle","label":"Article Title"},{"value":"Drug Discovery Today","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drudis.2025.104456","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"104456"}}